Accuray reported a total net revenue of $86.5 million for Q1 FY2027, down 8% year-over-year, mainly due to a 26% drop in product revenue. However, service revenue grew 4%, and service gross margin improved to 35.1%. Operating expenses fell 29% excluding a $35.4 million goodwill impairment charge, reflecting successful transformation initiatives. The company strengthened its financial position through a $15 million investment and debt restructuring, and it aims to convert commercial engagement into stronger product sales and revenue growth in FY2027.
Accuray's Q1 FY2027 financial results show a total net revenue of $86.5 million, down 8% year-over-year, with a 26% drop in product revenue but a 4% increase in service revenue and improved service gross margin at 35.1%. For readers following the health sector, here is Pluang's market snapshot as of Nov 05, 2026 04:11 WIB: out of 150 priced US health stocks, 108 rose and 42 fell. Notable movers include Acadia Healthcare Company Inc (ACHC) at USD 34.56 with a 16.68% increase, Moderna, Inc. (MRNA) at USD 258.08 up 12.97%, and Bruker Corporation (BRKR) at USD 63.77 up 12.87%.
NOVAGOLD shareholders approved a transaction for New NOVAGOLD to acquire the remaining 40% interest in the Donlin Gold project from Paulson Advisers, increasing NOVAGOLD's ownership from 60% to 100%. This consolidation makes New NOVAGOLD the ultimate...
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
3M Company has reached a historic $7.35 billion settlement to resolve personal injury claims related to exposure to PFAS, toxic chemicals known as "forever chemicals." The settlement covers about 99% of existing claims, potentially benefiting 115,000...
The global e-learning market is projected to grow from $275.9 billion in 2026 to $506.6 billion by 2032, with a CAGR of 10.62% driven by rising internet connectivity, corporate upskilling demands, and government digital education initiatives. North A...
Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, focusing on de-risked, post-proof-of-concept assets. The company offers investors exposure to blockbuster therapies with attractive risk-adjusted returns, including aro...
